WO2007081790A3 - Procedes de diagnostic et de traitement du cancer de la prostate - Google Patents

Procedes de diagnostic et de traitement du cancer de la prostate Download PDF

Info

Publication number
WO2007081790A3
WO2007081790A3 PCT/US2007/000255 US2007000255W WO2007081790A3 WO 2007081790 A3 WO2007081790 A3 WO 2007081790A3 US 2007000255 W US2007000255 W US 2007000255W WO 2007081790 A3 WO2007081790 A3 WO 2007081790A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
diagnosing
methods
gpc3
treating prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/000255
Other languages
English (en)
Other versions
WO2007081790A2 (fr
Inventor
Bruce Wang
Matthias Wabl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picobella LLC
Original Assignee
Picobella LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picobella LLC filed Critical Picobella LLC
Priority to EP07716350A priority Critical patent/EP1977247A4/fr
Priority to CA002640932A priority patent/CA2640932A1/fr
Publication of WO2007081790A2 publication Critical patent/WO2007081790A2/fr
Publication of WO2007081790A3 publication Critical patent/WO2007081790A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés de diagnostic et de traitement du cancer de la prostate. Dans la mise en pratique du procédé, le taux de la protéine GPC3 est dosé dans un échantillon des liquides organiques d'un sujet et le taux de GPC3 observé est utilisé pour déterminer si le sujet présente un taux élevé de GPC3 associé au cancer de la prostate. Selon la présente invention, les patients qui présentent de tels taux élevés peuvent être traités avec divers agents immuno-thérapeutiques liés à la GPC3.
PCT/US2007/000255 2006-01-04 2007-01-04 Procedes de diagnostic et de traitement du cancer de la prostate Ceased WO2007081790A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07716350A EP1977247A4 (fr) 2006-01-04 2007-01-04 Procedes de diagnostic et de traitement du cancer de la prostate
CA002640932A CA2640932A1 (fr) 2006-01-04 2007-01-04 Procedes de diagnostic et de traitement du cancer de la prostate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/325,847 2006-01-04
US11/325,847 US7723043B2 (en) 2006-01-04 2006-01-04 Methods for screening for prostate cancer

Publications (2)

Publication Number Publication Date
WO2007081790A2 WO2007081790A2 (fr) 2007-07-19
WO2007081790A3 true WO2007081790A3 (fr) 2007-09-27

Family

ID=38224917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000255 Ceased WO2007081790A2 (fr) 2006-01-04 2007-01-04 Procedes de diagnostic et de traitement du cancer de la prostate

Country Status (4)

Country Link
US (2) US7723043B2 (fr)
EP (1) EP1977247A4 (fr)
CA (1) CA2640932A1 (fr)
WO (1) WO2007081790A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174783A1 (fr) 2012-05-23 2013-11-28 Pieris Ag Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3088890B1 (fr) 2013-12-24 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Méthode de mesure de protéine gpc3 soluble
KR102366820B1 (ko) * 2014-01-17 2022-02-22 미노믹 인터내셔널 리미티드 진단을 위한 세포 표면 전립선암 항원
EP2944652A1 (fr) * 2014-05-13 2015-11-18 Technische Universität München Récepteurs de lymphocytes T glypican-3-spécifiques et leurs utilisations pour l'immunothérapie du carcinome hépatocellulaire
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN105759051B (zh) * 2016-02-25 2018-12-18 广州科方生物技术股份有限公司 一种磷脂酰肌醇蛋白聚糖-3的定量分析试剂盒及其制备方法
CN110577600B (zh) * 2018-06-07 2021-05-04 中国科学院上海药物研究所 靶向gpc3的抗体-药物偶联物及其制备方法和用途
CA3170023A1 (fr) * 2020-02-27 2021-09-02 Nanjing Legend Biotech Co., Ltd. Anticorps et recepteurs antigeniques chimeriques ciblant le glypicane-3 (gpc3) et leurs procedes d'utilisation
EP4279504A4 (fr) 2021-01-18 2024-11-27 Fujirebio Inc. Procédé de traitement d'échantillons solubles contenant gpc3 dans des dosages immunologiques de gpc3 solubles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040236080A1 (en) * 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3332167B2 (ja) * 1992-10-30 2002-10-07 和光純薬工業株式会社 マイクロプレートリーダー
FR2781885B1 (fr) * 1998-07-28 2000-09-08 Jacques Toledano Dispositif et procede electrostatiques de detection immunologique fine
CA2427858A1 (fr) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Methodes et compositions destinees a inhiber grb7
WO2004022597A1 (fr) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Anticorps d'un peptide n-terminal du gpc3 solubilise dans le sang
AU2002330482A1 (en) * 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040236080A1 (en) * 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAKATSURA ET AL.: "Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 306, no. 1, 20 June 2003 (2003-06-20), pages 16 - 25, XP002261242 *
VEUGELERS ET AL.: "Mutational analysis of the GPC3/GPC4 glypica gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: Identification of loss-of-function mutations in the GPC3 gene", HUMAN MOLECULAR GENETICS, vol. 9, no. 9, 22 May 2000 (2000-05-22), pages 1321 - 1328, XP002528529 *

Also Published As

Publication number Publication date
WO2007081790A2 (fr) 2007-07-19
US20100041126A1 (en) 2010-02-18
EP1977247A2 (fr) 2008-10-08
EP1977247A4 (fr) 2009-07-08
US7723043B2 (en) 2010-05-25
US20070154964A1 (en) 2007-07-05
CA2640932A1 (fr) 2007-07-19

Similar Documents

Publication Publication Date Title
WO2008140774A3 (fr) Procédés de diagnostic et de traitement du cancer de la prostate et du cancer du poumon
WO2004088309A3 (fr) Methodes de diagnostic de troubles du tractus urinaire et de la prostate
WO2008070001A3 (fr) Procédés et appareils de stimulation magnétique transcrânienne (tms)
WO2004031410A3 (fr) Methode permettant de diagnostiquer des seminomes du testicule
AU2003263603A1 (en) Method for diagnosing pancreatic cancer
WO2004055196A3 (fr) Procedes d'identification du risque de cancer du sein et traitements associes
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
WO2005117938A3 (fr) Methodes de traitement des pathologies oculaires
WO2004098377A3 (fr) Procedes et compositions pour le diagnostic et la therapie de troubles lies a la parkine
WO2004031414A3 (fr) Technique de diagnostic du cancer de la prostate
WO2007013575A3 (fr) Procede pour le diagnostic et le traitement d'hypernephrome
WO2007081790A3 (fr) Procedes de diagnostic et de traitement du cancer de la prostate
WO2003000117A3 (fr) Detection et traitement du cancer de la prostate
WO2004043232A3 (fr) Methodes servant a identifier des risques de melanomes et traitements correspondant
WO2005014846A3 (fr) Procedes pour reperer le risque de cancer du sein et traitements correspondants
WO2001065998A3 (fr) Methodes de diagnostic et de traitement du cancer du sein
WO2009027703A3 (fr) Identification d'une lésion d'un organe
WO2005089310A3 (fr) Test pour identifier la mauvaise haleine
WO2010102160A3 (fr) Procédé de diagnostic utilisant palb2
WO2004038045A3 (fr) Methode de diagnostic de cancers gastriques de type diffus
WO2008115478A3 (fr) Procédé de détection et de traitement du cancer
WO2004079329A3 (fr) Identification de composes therapeutiques
WO2002063048A3 (fr) Procedes pour predire la sensibilite des tumeurs a la privation en arginine
WO2004039312A3 (fr) Optineurine et glaucome
WO2004048546A3 (fr) Procedes permettant de detecter le risque de cancer du sein et traitements pour ce dernier

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2640932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007716350

Country of ref document: EP